238 related articles for article (PubMed ID: 32375124)
1. Exosomal long non-coding RNA MSTRG.292666.16 is associated with osimertinib (AZD9291) resistance in non-small cell lung cancer.
Deng Q; Fang Q; Xie B; Sun H; Bao Y; Zhou S
Aging (Albany NY); 2020 May; 12(9):8001-8015. PubMed ID: 32375124
[TBL] [Abstract][Full Text] [Related]
2. Exosomal microRNAs as potential biomarkers for osimertinib resistance of non-small cell lung cancer patients.
Janpipatkul K; Trachu N; Watcharenwong P; Panvongsa W; Worakitchanon W; Metheetrairut C; Oranratnachai S; Reungwetwattana T; Chairoungdua A
Cancer Biomark; 2021; 31(3):281-294. PubMed ID: 33896827
[TBL] [Abstract][Full Text] [Related]
3. Exosome-derived miR-210 involved in resistance to osimertinib and epithelial-mesenchymal transition in EGFR mutant non-small cell lung cancer cells.
Hisakane K; Seike M; Sugano T; Yoshikawa A; Matsuda K; Takano N; Takahashi S; Noro R; Gemma A
Thorac Cancer; 2021 Jun; 12(11):1690-1698. PubMed ID: 33939301
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of circular RNA profiling in AZD9291-resistant non-small cell lung cancer cell lines.
Chen T; Luo J; Gu Y; Huang J; Luo Q; Yang Y
Thorac Cancer; 2019 Apr; 10(4):930-941. PubMed ID: 30883029
[TBL] [Abstract][Full Text] [Related]
5. CircMYBL1 suppressed acquired resistance to osimertinib in non-small-cell lung cancer.
Li Y; Wang N; Huang Y; He S; Bao M; Wen C; Wu L
Cancer Genet; 2024 Jun; 284-285():34-42. PubMed ID: 38626533
[TBL] [Abstract][Full Text] [Related]
6. Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer.
Wu S; Luo M; To KKW; Zhang J; Su C; Zhang H; An S; Wang F; Chen D; Fu L
Mol Cancer; 2021 Jan; 20(1):17. PubMed ID: 33461557
[TBL] [Abstract][Full Text] [Related]
7. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
8. [Lnc-TMEM132D-AS1 overexpression reduces sensitivity of non-small cell lung cancer cells to osimertinib].
Zhao Q; Wang N; Li Y; Wu Q; Wu L
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Feb; 43(2):242-250. PubMed ID: 36946044
[TBL] [Abstract][Full Text] [Related]
9. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
Li XF; Shen WZ; Jin X; Ren P; Zhang J
Sci Rep; 2020 Jul; 10(1):11236. PubMed ID: 32641854
[TBL] [Abstract][Full Text] [Related]
10. Exosomal long non-coding RNA SOX2 overlapping transcript enhances the resistance to EGFR-TKIs in non-small cell lung cancer cell line H1975.
Zhou D; Xia Z; Xie M; Gao Y; Yu Q; He B
Hum Cell; 2021 Sep; 34(5):1478-1489. PubMed ID: 34244990
[TBL] [Abstract][Full Text] [Related]
11. ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.
Liu K; Chen X; Wu L; Chen S; Fang N; Cai L; Jia J
BMC Pulm Med; 2021 May; 21(1):163. PubMed ID: 33992097
[TBL] [Abstract][Full Text] [Related]
12. Exosome-mediated transfer of lncRNA RP11‑838N2.4 promotes erlotinib resistance in non-small cell lung cancer.
Zhang W; Cai X; Yu J; Lu X; Qian Q; Qian W
Int J Oncol; 2018 Aug; 53(2):527-538. PubMed ID: 29845246
[TBL] [Abstract][Full Text] [Related]
13. Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR-mutant non-small cell lung cancer.
Qin Q; Li X; Liang X; Zeng L; Wang J; Sun L; Zhong D
Thorac Cancer; 2021 Jun; 12(11):1708-1715. PubMed ID: 33943009
[TBL] [Abstract][Full Text] [Related]
14. Exosomes derived from M2 type tumor-associated macrophages promote osimertinib resistance in non-small cell lung cancer through MSTRG.292666.16-miR-6836-5p-MAPK8IP3 axis.
Wan X; Xie B; Sun H; Gu W; Wang C; Deng Q; Zhou S
Cancer Cell Int; 2022 Feb; 22(1):83. PubMed ID: 35168607
[TBL] [Abstract][Full Text] [Related]
15. Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling.
Takahashi S; Noro R; Seike M; Zeng C; Matsumoto M; Yoshikawa A; Nakamichi S; Sugano T; Hirao M; Matsuda K; Hamada M; Gemma A
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33924522
[TBL] [Abstract][Full Text] [Related]
16. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P
Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353
[TBL] [Abstract][Full Text] [Related]
17. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
Liu Z; Gao W
Arch Toxicol; 2019 Jun; 93(6):1555-1571. PubMed ID: 30993382
[TBL] [Abstract][Full Text] [Related]
18. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
19. Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer.
Lei Y; Guo W; Chen B; Chen L; Gong J; Li W
Oncol Rep; 2018 Dec; 40(6):3438-3446. PubMed ID: 30542738
[TBL] [Abstract][Full Text] [Related]
20. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]